奥沙利铂联合卡培他滨治疗进展期胃癌的临床观察.pdf

文档介绍：现代肿瘤医学 2011年7月第l9卷第7期 MODERNONCOLOGY,。。 ·1381· 奥沙利铂联合卡培他滨治疗进展期胃癌的临床观察陈志军,高亚丽 binationwithcapecitabinechemotherapyfor ancer(AGC) CHENZhi—iun,GA0Ya一1i DepartmentofOncology,LuoyangCentreHospital,Henanlatoyang471000,China. 【Abstract】0bjective:Toinvestigatetheefficacy,binationwith :Totalof45patientswithAGCwereenteredintothisstudy. Theyreceived2hintravenousinfusionofoxaliplatin130mg/m2onday1andoraladministrationofeapecitabine2000 mg/m,givenintwodailydoses,ondays1—14(XELOXregimen).Theregimenwasrepeatedevery21days. : (CR),25partialresponse(PR),14stabledisease(SD)and3progressdisease(PD).Theirfollow—uptime were12months,, monadverseeventsweremyelosuppression,peripheralneuropathy,diarrhea,nausea/vomiting,andhand :XELOXisalleffectiveandwelltoleratedfirst—linechemotherapyregimenforpa— . 【Keywords】oxaliplatin;capecitabine;AGC ModemOncology2011,19(07):1381—1383 【摘要】目的:评价奥沙利铂联合卡培他滨治疗进展期胃癌的疗效、不良反应和安全性。方法:45例进展期胃癌(AGC)患者采用奥沙利铂联合卡培他滨(XELOX)方案化疗,奥沙利铂130mg/m,静脉滴注2h,d;卡培他滨2000me/m,分2次口服,d ,21天为一个周期,2个周期后评价疗效。结果:45例中有43例可评价疗效,获完全缓解(CR)1例(%),部分缓解(PR)25例(%),无变化(sD)14例(%),进展(PD)3例(%)。对所有患者随访1